J Gastroenterology: Vascular hemophilia factor antigen-platelet ratio (VITRO) score predicts liver loss and mortality in patients with cirrhosis

BACKGROUND: The ratio of vascular haemophilia factors to platelets (VTS) reflects the severity of hepatic fibrosis and high blood pressure in patients with cirrhosis and may therefore have prognostic valuemethod: Researchers recruited patients with compensating cirrhosisAt the beginning of the study, levels of VITRO, Child-Pugh scores (CPS) and MELD were determinedHepatic replacement disorder sydgins are defined as fluid bleeding, ascites, or hepatic encephalopathyRecord liver transplants and deathsresults: This study included 194 patients with cirrhosis (CPS-A 89%, B 11%; 56% for men; 56% for median age; 50% for varicose veins)During the 45-month median follow-up period, 35 cases (18%) and 14 (7%) patients diedIn patients with n-88 (45%) VITROSE-2.5, the risk of liver loss was significantly increased (p 0.001)Patients with VITRO 2.5 were more likely to lose compensation, at 9% (95% CI 3-16%) in 1 year, 18% (95% CI 10-27%) in 2 years, and 4% (95% CI 0-8%) in patients with VITROV 2.5The estimated 1-year/2-year survival rate for patients with VITRO 2.5 was 98% (95% CI 95-100%) and 94% (95% CI 88-99%), while the survival rate of PATIENTs with VITRO 2.5 was 100% (p .001)Vitrox 2.5 can still be used as an important predictor of mortality in patients without liver transplantation (HR 1.38, CI 1.09-1.76; p - 0.007)The risk of liver failure in patients who eradicate hepatitis C offspring and VITRO2.1 is still significantly increased (p0.033)conclusion: "The VITROIst is a prognostic tool for assessing the risk of failure and death in patients with valuable cirrhosis, including the environment after hepatitis C eradication."